Propanc Biopharma shares surge 41.36% premarket after unveiling PRP therapy with 85% tumor growth inhibition and FDA Orphan Drug Designation for pancreatic cancer.

Propanc Biopharma surged 41.36% in premarket trading following the announcement of its lead proenzyme therapy PRP, a novel treatment targeting pancreatic cancer with demonstrated preclinical efficacy, including over 85% tumor growth inhibition. The company highlighted PRP’s potential to address unmet needs in the $3.25 billion pancreatic cancer market, which is projected to grow to $10.25 billion by 2034. PRP, which received FDA Orphan Drug Designation in 2017, is set to enter a Phase 1b First-In-Human trial in 2026 at a leading Melbourne cancer center. The therapy’s differentiated mechanism—targeting cancer stem cells and altering the tumor microenvironment—positions it as a potential alternative to conventional treatments with reduced toxicity. Strengthening intellectual property and the trial’s initiation underscore Propanc’s strategic momentum, aligning with investor optimism for its long-term commercial and therapeutic potential.